These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38666379)

  • 1. Antiarrhythmic and Anti-Inflammatory Effects of Sacubitril/Valsartan on Post-Myocardial Infarction Scar.
    Martínez-Falguera D; Aranyó J; Teis A; Ferrer-Curriu G; Monguió-Tortajada M; Fadeuilhe E; Rodríguez-Leor O; Díaz-Güemes I; Roura S; Villuendas R; Sarrias A; Bazan V; Delgado V; Bayes-Genis A; Bisbal F; Gálvez-Montón C
    Circ Arrhythm Electrophysiol; 2024 May; 17(5):e012517. PubMed ID: 38666379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sacubitril/Valsartan Averts Adverse Post-Infarction Ventricular Remodeling and Preserves Systolic Function in Rabbits.
    Torrado J; Cain C; Mauro AG; Romeo F; Ockaili R; Chau VQ; Nestler JA; Devarakonda T; Ghosh S; Das A; Salloum FN
    J Am Coll Cardiol; 2018 Nov; 72(19):2342-2356. PubMed ID: 30384891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative and Combinatorial Effects of Resveratrol and Sacubitril/Valsartan alongside Valsartan on Cardiac Remodeling and Dysfunction in MI-Induced Rats.
    Raj P; Sayfee K; Parikh M; Yu L; Wigle J; Netticadan T; Zieroth S
    Molecules; 2021 Aug; 26(16):. PubMed ID: 34443591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection of Sacubitril/Valsartan against Pathological Cardiac Remodeling by Inhibiting the NLRP3 Inflammasome after Relief of Pressure Overload in Mice.
    Li X; Zhu Q; Wang Q; Zhang Q; Zheng Y; Wang L; Jin Q
    Cardiovasc Drugs Ther; 2020 Oct; 34(5):629-640. PubMed ID: 32444995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin Receptor Neprilysin Inhibitor Attenuates Myocardial Remodeling and Improves Infarct Perfusion in Experimental Heart Failure.
    Pfau D; Thorn SL; Zhang J; Mikush N; Renaud JM; Klein R; deKemp RA; Wu X; Hu X; Sinusas AJ; Young LH; Tirziu D
    Sci Rep; 2019 Apr; 9(1):5791. PubMed ID: 30962467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sacubitril/valsartan inhibits obesity-associated diastolic dysfunction through suppression of ventricular-vascular stiffness.
    Aroor AR; Mummidi S; Lopez-Alvarenga JC; Das N; Habibi J; Jia G; Lastra G; Chandrasekar B; DeMarco VG
    Cardiovasc Diabetol; 2021 Apr; 20(1):80. PubMed ID: 33882908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LCZ696 Therapy Reduces Ventricular Tachyarrhythmia Inducibility in a Myocardial Infarction-Induced Heart Failure Rat Model.
    Chang PC; Lin SF; Chu Y; Wo HT; Lee HL; Huang YC; Wen MS; Chou CC
    Cardiovasc Ther; 2019; 2019():6032631. PubMed ID: 31772612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of A2B adenosine receptor reduces left ventricular dysfunction and ventricular arrhythmias 1 week after myocardial infarction in the rat model.
    Zhang H; Zhong H; Everett TH; Wilson E; Chang R; Zeng D; Belardinelli L; Olgin JE
    Heart Rhythm; 2014 Jan; 11(1):101-9. PubMed ID: 24120874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin Receptor-Neprilysin Inhibition Attenuates Right Ventricular Remodeling in Pulmonary Hypertension.
    Sharifi Kia D; Benza E; Bachman TN; Tushak C; Kim K; Simon MA
    J Am Heart Assoc; 2020 Jul; 9(13):e015708. PubMed ID: 32552157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sacubitril/valsartan reduces susceptibility to atrial fibrillation by improving atrial remodeling in spontaneously hypertensive rats.
    Li Q; Fang Y; Peng DW; Li LA; Deng CY; Yang H; Kuang SJ; Li QQ; Zhang MZ; Zeng P; Zhang QH; Liu Y; Deng H; Wei W; Xue YM; Wu SL; Rao F
    Eur J Pharmacol; 2023 Aug; 952():175754. PubMed ID: 37182595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of Sacubitril/Valsartan on cardiac fibrosis early after myocardial infarction in hypertensive rats.
    Liu Y; Zhong C; Si J; Chen S; Kang L; Xu B
    J Hypertens; 2022 Sep; 40(9):1822-1830. PubMed ID: 35943105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-dimensional cardiac fibre disorganization as a novel parameter for ventricular arrhythmia stratification after myocardial infarction.
    León DG; López-Yunta M; Alfonso-Almazán JM; Marina-Breysse M; Quintanilla JG; Sánchez-González J; Galán-Arriola C; Castro-Núñez F; González-Ferrer JJ; Ibáñez B; Pérez-Villacastín J; Pérez-Castellano N; Fuster V; Jalife J; Vázquez M; Aguado-Sierra J; Filgueiras-Rama D
    Europace; 2019 May; 21(5):822-832. PubMed ID: 30649290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sacubitril/valsartan attenuates atrial electrical and structural remodelling in a rabbit model of atrial fibrillation.
    Li LY; Lou Q; Liu GZ; Lv JC; Yun FX; Li TK; Yang W; Zhao HY; Zhang L; Bai N; Zhan CC; Yu J; Zang YX; Li WM
    Eur J Pharmacol; 2020 Aug; 881():173120. PubMed ID: 32325147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electrical homogenization of ventricular scar by application of collagenase: a novel strategy for arrhythmia therapy.
    Yagishita D; Ajijola OA; Vaseghi M; Nsair A; Zhou W; Yamakawa K; Tung R; Mahajan A; Shivkumar K
    Circ Arrhythm Electrophysiol; 2013 Aug; 6(4):776-83. PubMed ID: 23873142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sacubitril/valsartan mitigates cardiac remodeling, systolic dysfunction, and preserves mitochondrial quality in a rat model of mitral regurgitation.
    Tantisuwat L; Saengklub N; Boonpala P; Kumphune S; Panyasing Y; Kalandakanond-Thongsong S; Kijtawornrat A
    Sci Rep; 2023 Jul; 13(1):11472. PubMed ID: 37455281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined levosimendan and Sacubitril/Valsartan markedly protected the heart and kidney against cardiorenal syndrome in rat.
    Sung PH; Chai HT; Yang CC; Chiang JY; Chen CH; Chen YL; Yip HK
    Biomed Pharmacother; 2022 Apr; 148():112745. PubMed ID: 35202913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of LCZ696, a dual angiotensin receptor neprilysin inhibitor, on isoproterenol-induced cardiac hypertrophy, fibrosis, and hemodynamic change in rats.
    Miyoshi T; Nakamura K; Miura D; Yoshida M; Saito Y; Akagi S; Ohno Y; Kondo M; Ito H
    Cardiol J; 2019; 26(5):575-583. PubMed ID: 29718530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sacubitril/Valsartan inhibits M1 type macrophages polarization in acute myocarditis by targeting C-type natriuretic peptide.
    Liu C; Long Q; Yang H; Yang H; Tang Y; Liu B; Zhou Z; Yuan J
    Biomed Pharmacother; 2024 May; 174():116535. PubMed ID: 38581923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor Sacubitril/Valsartan.
    Clements RT; Vang A; Fernandez-Nicolas A; Kue NR; Mancini TJ; Morrison AR; Mallem K; McCullough DJ; Choudhary G
    Circ Heart Fail; 2019 Nov; 12(11):e005819. PubMed ID: 31707802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sacubitril/Valsartan Improves Cardiac Function and Decreases Myocardial Fibrosis Via Downregulation of Exosomal miR-181a in a Rodent Chronic Myocardial Infarction Model.
    Vaskova E; Ikeda G; Tada Y; Wahlquist C; Mercola M; Yang PC
    J Am Heart Assoc; 2020 Jul; 9(13):e015640. PubMed ID: 32538237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.